Hamilton and Bionano Genomics Announce World’s First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM
June 09 2022 - 9:00AM
Hamilton and Bionano Genomics, Inc. (Nasdaq: BNGO) today
announced the collaborative development of the Long String VANTAGE
for the isolation of Ultra High Molecular Weight (UHMW) DNA for use
in optical genome mapping (OGM).
Extraction of UHMW DNA of high quality and quantity is an
important prerequisite and first step in Bionano’s sample
preparation workflow. UHMW DNA extraction is generally performed
manually by highly trained and experienced laboratory personnel,
limiting volume and application in routine sample preparation.
By combining Hamilton’s long-standing expertise in automating
genomic workflows through precision engineering of automated liquid
handling solutions and consumables, and Bionano’s knowledge in
extraction, enzymatic treatment and analysis of UHMW DNA molecules,
the companies have developed the world’s first walk-away automation
solution for UHMW DNA extraction.
Hamilton’s Long String VANTAGE is the first Assay Ready
Workstation solution in Hamilton’s Long String Genomics product
program and supports extraction of UHMW DNA at increased scale.
Running the Bionano Prep SP Blood and Cell Culture DNA Isolation
Kit, customers can obtain up to 12 UHMW DNA samples in less than 4
hours with high consistency and reproducibility. This workflow has
the potential to double manual output, with increased confidence in
sample yields and DNA quality.
The companies plan to collaborate with select clinical research
laboratories to test and further develop applications for the use
of the Long String VANTAGE and the Bionano Prep SP kits and
anticipate commercial release of some of these workflows by the end
of 2022.
“Hamilton is highly committed to empowering genomic sciences and
diagnostics with innovative products and applications by
collaborating with leading kit and technology providers,” Dr.
Martin Frey, CEO Hamilton Bonaduz AG said in a statement.
“Analyzing ultra-long DNA molecules by Optical Genome Mapping or
genome sequencing technologies is providing insight into previously
unresolved questions about genome biology and structural
aberrations of the genome with clinical relevance. We are extremely
pleased to partner with Bionano Genomics in addressing this
innovation area.”
“The outcomes of this partnership with Hamilton are outstanding.
They have shown an exceptional ability to improve workflows through
the automation of UHMW DNA isolation, which consistently results in
extremely long and pure DNA molecules that are suitable for use in
OGM. We expect this innovation will significantly reduce time to
results, reduce hands-on time and improve OGM performance by
standardizing the process of UHMW DNA isolation. Bionano and
Hamilton look forward to seeing customers adopt the Long String
VANTAGE solution,” commented Erik Holmlin, PhD, president and
chief executive officer of Bionano Genomics.
About HamiltonHamilton is a leading global
manufacturer, providing automated liquid handling workstations and
laboratory automation technology to the scientific community. With
a focus on innovative design, Hamilton products incorporate
patented liquid handling technologies into a portfolio that
includes liquid handling platforms, standard application-based
solutions, small devices, consumables, and OEM liquid handling
solutions. Known for advancing life science, clinical diagnostics,
forensics and biotechnology industries, Hamilton products offer
reliability, performance, and flexibility. Ensuring a continuous
commitment to quality, Hamilton utilizes state-of-the-art
manufacturing at production facilities in Reno, Nevada and Bonaduz,
Switzerland and has earned a global ISO 9001 certification.
Privately held, Hamilton maintains headquarters in Reno, Nevada;
Franklin, Massachusetts; and Bonaduz, Switzerland, along with
subsidiary offices throughout the world.
www.hamiltoncompany.com/robotics
About Bionano Genomics, Inc.Bionano
Genomics is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen business, the Company also provides
diagnostic testing for patients with clinical presentations
consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information,
visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “can,” “potential,” “plan,” “expect,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the anticipated benefits and improvements
resulting from the use of Hamilton’s Long String VANTAGE, or the
ability of that system to reliably and consistently isolate high
quality and sufficient quantity of UHMW DNA for use with optical
genome mapping. Each of these forward-looking statements involves
risks and uncertainties. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of the COVID-19
pandemic on our business and the global economy; general market
conditions; changes in the competitive landscape and the
introduction of competitive technologies or improvements in
existing technologies; changes in our strategic and commercial
plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts; the ability of
medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024